Avance Clinical to Meet European Biotechs at ESMO 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of Excellence

“European biotechs are deciding how and where to advance their oncology assets,” said Dr Peoples. “We support them from preclinical planning through to the end of Phase II, with continuity of leadership at every step.”

The Center brings together scientific, medical, regulatory, and operational leadership. Its capabilities include:

• complex early-phase designs, including adaptive and Bayesian dose escalation
• translational and biomarker strategy
• disciplined patient selection
• oncology-focused site networks across Australia, New Zealand, Asia Pacific, North America, and Europe

The team has delivered more than 260 oncology trials in five years, across solid tumors (including non-small cell lung cancer, melanoma, ovarian cancer, glioblastoma and hepatocellular carcinoma), hematological malignancies (including multiple myeloma, lymphoma and leukemia), and novel modalities such as RNAi, cell-based therapies and targeted small molecules. Sponsors can start fast in Australia and New Zealand, or begin wherever their program fits best, with one team throughout.
European biotech leaders attending ESMO can schedule a meeting with Dr Peoples.